Results 1 to 10 of about 8,387 (243)

Effects of trimetazidine on oxidant-antioxidant balance and angiogenesis; an in vivo experimental study [PDF]

BMC Cardiovascular Disorders
Background We evaluated the effects of trimetazidine (TMZ) on the oxidative-antioxidative balance and angiogenesis in an in vivo experimental model. This study aims to evaluate the effects of trimetazidine on angiogenesis through histological analysis ...
Fethullah Kayan, Hasan Basri Savas
doaj   +3 more sources

Pleiotropic effects of trimetazidine

Российский кардиологический журнал, 2013
Aim. To investigate potential pleiotropic effects of trimetazidine (PreductalMB) in patients with stable effort angina. Material and methods. This randomised controlled clinical study included 95 patients with Functional Class I–III stable effort angina ...
O. V. Romashchenko, G. N. Klochkova, E. I. Mukhanova, I. V. Gaivoronskaya   +3 more
doaj   +4 more sources

Long-term risk of malignancies in persons with ischemic heart disease treated with trimetazidine dihydrochloride [PDF]

Communications Medicine
Background Metabolic reprogramming of energy processes is a cellular hallmark of various cancers. Whether trimetazidine, an anti-ischemic agent that preferentially potentiates cellular glucose oxidation, alters the long-term risk of malignancies is ...
Yuen-Ting Cheng, Chun-Fung Sin, Edmond S. K. Ma, Stephen T. S. Lam, Shiu-Lun Au Yeung, Bernard M. Y. Cheung, Hung-Fat Tse, Kai-Hang Yiu, Yap-Hang Chan   +8 more
doaj   +10 more sources

Trimetazidine in Heart Failure [PDF]

Frontiers in Pharmacology, 2021
Heart failure is a systemic syndrome caused by multiple pathological factors. Current treatments do not have satisfactory outcomes. Several basic studies have revealed the protective effect of trimetazidine on the heart, not only by metabolism modulation but also by relieving myocardial apoptosis, fibrosis, autophagy, and inflammation. Clinical studies
Hongyang Shu, Hongyang Shu, Yizhong Peng, Weijian Hang, Weijian Hang, Ning Zhou, Ning Zhou, Dao Wen Wang, Dao Wen Wang   +8 more
openaire   +4 more sources

Trimetazidine Is Associated With Ameliorated Stroke Risk in Patients With Both Ischemic Heart Disease and Atrial Fibrillation [PDF]

Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease
Background Myocardial ischemia is closely associated with arrhythmogenesis and prognostication in patients with atrial fibrillation (AF). Trimetazidine ameliorates myocardial ischemia through prioritizing cardiomyocyte metabolism to glucose oxidation ...
Yuen‐Ting Cheng, Gregory Y. H. Lip, Bernard M. Y. Cheung, Kai‐Hang Yiu, Hung‐Fat Tse, Yap‐Hang Chan   +5 more
doaj   +2 more sources

Trimetazidine in cardiovascular medicine

International Journal of Cardiology, 2019
Abnormalities of myocardial energy metabolism appear as a common background of the two major cardiac disorders: ischemic heart disease (IHD) and heart failure (HF). Myocardial ischemia has been recently conceived as a multifaceted syndrome that can be precipitated by a number of mechanisms including metabolic abnormalities. HF is a progressive disorder
Jamshed Dalal, Yuri Lopatin
exaly   +6 more sources

Mortality differences in coronary patients with breast cancer treated with trimetazidine dihydrochloride: potential therapeutic implications [PDF]

Cardio-Oncology
Background Trimetazidine, an anti-angina drug with metabolic regulatory effects, has been observationally associated with reduced malignancy risk. However, whether it has clinical implications for established breast cancer is unknown.
Yuen-Ting Cheng, Chun-Fung Sin, Edmond S. K. Ma, Stephen T. S. Lam, Bernard MY Cheung, Kai-Hang Yiu, Hung-Fat Tse, Yap-Hang Chan   +7 more
doaj   +2 more sources

Evaluation of trimetazidine in alleviating paclitaxel-induced peripheral neuropathy in breast cancer patients: a randomized controlled trial [PDF]

Frontiers in Pharmacology
BackgroundPaclitaxel-induced peripheral neuropathy is a frequent chemotherapy complication that causes nerve damage and profoundly reduces patients’ quality of life.
Asmaa N. Iqbal, Fatma M. Mady, Eman Mohamed Sadek, Noha M. Abdullah, Ahmad Mostafa Abdel-Azeez, Eman Shorog, Engy A. Wahsh   +6 more
doaj   +2 more sources

Trimetazidine Revisited: A Comprehensive Review of the Pharmacological Effects and Analytical Techniques for the Determination of Trimetazidine

Cardiovascular Therapeutics, 2008
Trimetazidine (TMZ) is an effective and well‐tolerated antianginal drug that possesses protective properties against ischemia‐induced heart injury. Growing interest in metabolic modulation in recent years urged an up‐to‐date review of the literature on TMZ. This review consists of two major sections: (1) comprehensive and critical information about the
Arzu Onay-Beşikçi, Sibel Özkan
exaly   +3 more sources

Trimetazidine Attenuates Heart Failure by Improving Myocardial Metabolism via AMPK

Frontiers in Pharmacology, 2021
Energic deficiency of cardiomyocytes is a dominant cause of heart failure. An antianginal agent, trimetazidine improves the myocardial energetic supply.
Hongyang Shu, Hongyang Shu, Weijian Hang, Weijian Hang, Yizhong Peng, Jiali Nie, Jiali Nie, Lujin Wu, Lujin Wu, Wenjun Zhang, Dao Wen Wang, Dao Wen Wang, Ning Zhou, Ning Zhou   +13 more
doaj   +1 more source